#United States #New York #Levi & Korsinsky #Securities Fraud #Intellia

Class Action Lawsuit Filed Against Intellia Therapeutics

Levi & Korsinsky, LLP has announced an important notification for shareholders of Intellia Therapeutics, Inc. (NTLA), a company specializing in innovative therapies. The firm has launched a class action lawsuit aimed at recovering losses for investors who have suffered due to alleged securities fraud occurring between July 30, 2024, and January 8, 2025. This issue highlights serious concerns regarding the transparency of information provided to investors about the company's ongoing research and development efforts.

Class Definition and Details

The lawsuit centers on claims of misinformation regarding Intellia's clinical development of the NTLA-3001 treatment, aimed at addressing alpha-1 antitrypsin deficiency (AATD) associated lung disease. During the specified period, the company communicated a positive outlook concerning the initiation of the Phase 1/2 study for NTLA-3001, suggesting that patient dosing would start in late 2024. However, crucial information was allegedly withheld, which has lead to investor losses.

Emergence of the Truth

The situation took a dramatic turn on January 9, 2025, when Intellia revealed a significant restructuring of its operations, including the decision to cease all research related to NTLA-3001. This decision followed revelations regarding a drastic decrease in demand for viral-based editing therapies, as non-viral alternatives gained traction within the scientific community. The announcement further revealed that Intellia would decrease its workforce by 27% in 2025. This abrupt shift caused the company’s share price to plummet from $12.02 to $10.20 in just two days, marking a significant loss for shareholders who relied on the previously provided information.

Next Steps for Affected Investors

Investors who experienced a financial setback due to these events have until April 14, 2025, to request the court designate them as lead plaintiffs in this class action. Notably, participation in any potential recovery does not necessitate serving as lead plaintiff, ensuring accessibility for all affected investors.

No Cost to Participate

Importantly, investors should note that participating in this class action does not require any upfront fees or costs. Levi & Korsinsky has established that compensation is available without financial obligations, permitting victims to seek justice without additional strain.

Why Choose Levi & Korsinsky?

With over two decades of experience in securities litigation, Levi & Korsinsky has built a formidable reputation. The law firm has successfully recovered hundreds of millions of dollars for aggrieved shareholders and remains recognized as one of the leading firms in the U.S. for securities class actions. Their team, comprising over 70 dedicated professionals, specializes in representing investors and fighting for their rights in complex legal scenarios.

Contact Information

For additional details, investors may reach out to Joseph E. Levi, Esq. at Levi & Korsinsky by calling (212) 363-7500 or via email at [email protected]. Those looking to submit information related to their claims can do so through the firm's dedicated submission link.

Intellia Therapeutics faces a challenging period as the company transitions following this lawsuit. For investors, understanding their rights and avenues for recourse is crucial in navigating the aftermath of stock fluctuations linked to corporate announcements and market demands.